- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT06888687
Vergleich der Unterstützung der Ernährung mit und ohne kontinuierliche Glukoseüberwachung bei Personen mit Typ -2 -Diabetes. (CARE-T2D)
Kontinuierliche Glukoseüberwachungsunterstützung remote E-Health-Diätetik, um Menschen mit Typ-2-Diabetes zu befähigen
A parallel, single-blinded, randomised clinical trial conducted remotely across Australia from the Mary MacKillop Institute for Health Research (MMIHR, Australian Catholic University) for individuals with type 2 diabetes, by researchers from Australian Catholic University, University of Adelaide, University of Queensland, University of Wollongong, Monash University, Monash Partners, Deakin University, La Trobe University and Melbourne University.
Studienübersicht
Status
Intervention / Behandlung
Detaillierte Beschreibung
In a parallel groups design, a total of 156 individuals will be recruited. After baseline pathology (HbA1c), blinded (Libre Pro iQ) continuous glucose monitoring (CGM) data and questionnaires (via REDCap) have been collected, participants will be randomised into one of two groups (DIET, dietetic support only; CGMD, CGM plus dietetic support). All participants will receive four (4) dietetic consults via telehealth at weeks 2, 6, 10 and 16, the content of which will be related to the randomised condition. Measurements will be repeated at 3 and 6 months from baseline to assess the changes in primary and secondary outcomes.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
Victoria
-
Melbourne, Victoria, Australien, 3065
- Australian Catholic University
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Aged 18+ years
- Reside anywhere in Australia and have a postal address
- Confirmed T2D diagnosis by a GP/endocrinologist
- Current HbA1c of ≥7.0%
- Have a smartphone and able to independently use it
Exclusion Criteria:
- Under the age of 18 years
- Use of insulin therapy (within the last three months) or medications which interfere with blood glucose levels (i.e. steroids)
- Use of CGM within the last six months
- Eating Disorder Examination Questionnaire (EDE-Q) global score >2.8 OR global score > or equal to 1.52, with sum of Q14-18 > or equal to 4
- Currently having ongoing consultations with an APD or have had a consult with an APD (within last three months)
- Not weight stable (>5 kg change over last three months)
- Severe hypoglycaemic event (i.e. requiring assistance) within last six months
- Change of antihyperglcyaemic medications within last three months
- Women who are pregnant or breastfeeding (within 24 weeks)
- History of psychotic disorder, or current diagnosis of other major psychiatric illness (e.g. mood disorder, eating disorder, substance use disorder)
- History of blood disorders (including but, not limited to, anemia and thalassemia) that impact the primary outcome (HbA1c)
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Doppelt
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Aktiver Komparator: Dietetic support only
This group is designed to act as a comparator using 'standard care' in dietetics practice. Dietary advice provided to this participant group will be performed by Accredited Practicing Dietitians (APDs) in line with evidence-based guidelines, specifically the T2DM best-practice guidelines plus Australian Dietary Guidelines (i.e. Australian Guide to Healthy Eating) to improve diet quality, and strategies to promote adherence. |
Dietary advice will be provided by Accredited Practicing Dietitians (APDs) in line with evidence-based guidelines, specifically the T2DM best-practice guidelines plus Australian Dietary Guidelines (i.e. Australian Guide to Healthy Eating) to improve diet quality, and strategies to promote adherence. |
|
Experimental: CGM plus dietetic support
The CGM plus dietetic support group will be provided 'standard care' dietetic support alongside the use, and interpretation of, the CGM data collected to assist in the understanding of dietary modifications on glucose management. As per the DIET group, dietary advice provided to this participant group will be performed by Accredited Practicing Dietitians (APDs) in line with evidence-based guidelines, specifically the T2DM best-practice guidelines plus Australian Dietary Guidelines (i.e. Australian Guide to Healthy Eating) to improve diet quality, and strategies to promote adherence. The CGM data collected via LibreLink will be used by both the participant and the dietitian to inform dietary modifications. |
Dietary advice will be provided by Accredited Practicing Dietitians (APDs) in line with evidence-based guidelines, specifically the T2DM best-practice guidelines plus Australian Dietary Guidelines (i.e. Australian Guide to Healthy Eating) to improve diet quality, and strategies to promote adherence. Abbott FreeStyle Libre 2+ CGM sensors will be used to provide feedback on interstitial glucose concentrations over 15 day periods per sensor. Nine sensors will be provided for the 6-month period, for 3 months of continuous use and 3 months of intermittent (2 weeks on - 2 weeks off) use. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
HbA1c
Zeitfenster: baseline, 6 months
|
Glycated haemoglobin concentration |
baseline, 6 months
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
HbA1c
Zeitfenster: 3 months
|
Glycated haemoglobin concentration |
3 months
|
|
24 h assessment of glycaemia
Zeitfenster: baseline, 6 months
|
24 h glucose measures assessed by blinded CGM (including, but not limited to, time in range, CV) |
baseline, 6 months
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
CGM application and use
Zeitfenster: From 0 to 26 weeks, per 2 week period of sensor use
|
number of days of CGM use and interaction with viewing CGM data (via LibreLink); CGMD group ony |
From 0 to 26 weeks, per 2 week period of sensor use
|
|
Per protocol analysis
Zeitfenster: 6 months
|
Primary analysis of the primary outcome (0-6 months HbA1c) is going to be intention to treat. Therefore, secondary analysis of all other variables will be a per-protocol (PP) analysis. Inclusion in PP analysis will be defined by: 1. Attendance at ≥3 dietetic consults, within ±10 days of the designated 2-, 6-, 10- and 16-week time points. |
6 months
|
|
Dietary intake
Zeitfenster: baseline, 3 months, 6 months
|
energy and macronutrient composition calculated from food records |
baseline, 3 months, 6 months
|
|
Fasting blood glucose
Zeitfenster: baseline, 3 months, 6 months
|
fasting blood glucose concentrations |
baseline, 3 months, 6 months
|
|
Adherence
Zeitfenster: baseline, 4 weeks, 8 weeks, 12 weeks, 16 weeks, 18 weeks, 20 weeks, 26 weeks
|
measures of adherence assessed by self-report (questionnaire) |
baseline, 4 weeks, 8 weeks, 12 weeks, 16 weeks, 18 weeks, 20 weeks, 26 weeks
|
|
hs-CRP
Zeitfenster: baseline, 3 months, 6 months
|
fasting high sensitive C-Peptide concentrations |
baseline, 3 months, 6 months
|
|
Fasting cholesterol
Zeitfenster: baseline, 3 months, 6 months
|
Fasting cholesterol concentrations (total, HDL and LDL) |
baseline, 3 months, 6 months
|
|
Fasting lipid concentration
Zeitfenster: baseline, 3 months, 6 months
|
fasting triglyceride concentrations |
baseline, 3 months, 6 months
|
|
Medication effect score (MES)
Zeitfenster: baseline, 6 months
|
Medication effect score for antihyperglycemic medications |
baseline, 6 months
|
|
Participant experience
Zeitfenster: 6 months
|
Qualitative semi-structured interviews |
6 months
|
|
Physical activity
Zeitfenster: baseline, 3 months, 6 months
|
Self-reported questionnaire (International Physical Activity Questionnaire (IPAQ) - Long Form) |
baseline, 3 months, 6 months
|
|
Sleep quality and quantity
Zeitfenster: baseline, 3 months, 6 months
|
Self-reported questionnaire (Pittsburgh Sleep Quality Index (PSQI)) |
baseline, 3 months, 6 months
|
|
Eating behaviours
Zeitfenster: baseline, 3 months, 6 months
|
Self-reported questionnaire (Eating Disorders Examination Questionnaire (EDEQ)) |
baseline, 3 months, 6 months
|
|
Health literacy
Zeitfenster: baseline, 3 months, 6 months
|
self-reported questionnaire (Health Literacy Questionnaire (HLQ)) |
baseline, 3 months, 6 months
|
|
Dietary quality
Zeitfenster: baseline, 3 months, 6 months
|
Assessed using the Healthy Eating Index For Australian adults (HEIFA) |
baseline, 3 months, 6 months
|
|
Diabetes self-management
Zeitfenster: baseline, 3 months, 6 months
|
Self-reported questionnaire (Diabetes Self-Management Questionnaire (DSMQ-R)) |
baseline, 3 months, 6 months
|
|
Diabetes distress
Zeitfenster: baseline, 3 months, 6 months
|
Self-reported questionnaire (Type 2 Diabetes Distress Assessment Scale (T2DDAS)) |
baseline, 3 months, 6 months
|
|
Overall well-being
Zeitfenster: baseline, 3 months, 6 months
|
Self-reported questionnaire (WHO-5) |
baseline, 3 months, 6 months
|
|
Diabetes-specific well-being
Zeitfenster: baseline, 3 months, 6 months
|
Self-reported questionnaire (DAWN Impact of Diabetes Profile (DIDP-7)) |
baseline, 3 months, 6 months
|
|
Treatment satisfaction
Zeitfenster: baseline, 3 months, 6 months
|
self-reported questionnaire (Diabetes Treatment Satisfaction Questionnaire (DTSQs (status) and DTSQc (change))) |
baseline, 3 months, 6 months
|
Mitarbeiter und Ermittler
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Erkrankungen des endokrinen Systems
- Stoffwechselerkrankungen
- Störungen des Glukosestoffwechsels
- Diabetes Mellitus
- Ernährungs- und Stoffwechselerkrankungen
- Diabetes mellitus, Typ 2
- Untersuchungstechniken
- Klinische Labortechniken
- Diagnosetechniken und Verfahren
- Diagnose
- Blutchemische Analyse
- Klinische Chemie -Tests
- Diagnosetechniken, endokrin
- Überwachung, physiologisch
- Kontinuierliche Glukoseüberwachung
Andere Studien-ID-Nummern
- 2024-3690HC
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
The data that support the findings of this study will be available from the corresponding author for a period of 36 months from publication, upon reasonable request for academic use. The data will not be made publicly available, as it contains information that could compromise research participant consent.
IPD-Sharing-Zugriffskriterien
Reasonable requests of data for academic use will be considered. Requests can be made to the corresponding author of the publication. Data will not be made publicly available as it contains information that could compromise research participant consent.
Art der unterstützenden IPD-Freigabeinformationen
- STUDIENPROTOKOLL
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .